Inhibikase Therapeutics (IKT) Interest Coverage Ratio Growth (1y) (2021 - 2025)
Inhibikase Therapeutics (IKT) Interest Coverage Ratio Growth (1y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | -347.04% |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 1,378.45% |
| 10 | Inhibikase Therapeutics | 400.61 Mn | 230.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -966.43% |
| Mar 31, 2025 | -2,886.27% |
| Sep 30, 2024 | 74.27% |
| Jun 30, 2024 | 82.66% |
| Mar 31, 2024 | -175.22% |
| Sep 30, 2023 | -130.15% |
| Mar 31, 2023 | 98.01% |
| Sep 30, 2022 | 99.77% |
| Mar 31, 2022 | -2,043.18% |
| Dec 31, 2021 | 260.99% |
| Sep 30, 2021 | -29,463.13% |
| Jun 30, 2021 | -546.13% |
| Mar 31, 2021 | -205.98% |